Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (431-440 of 466) with videos related to

Pageof 47
Sort By:
Blood|April 6, 2023
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemiaQu Jiang, Johanna Stachelscheid, Johannes Bloehdorn, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Leukemia & Lymphoma|March 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemiaFlorian Simon, Rudy Ligtvoet, Moritz Fürstenau, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|September 6, 2013
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndromeEkaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Lancet (London, England)|May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Nature Communications|January 19, 2023
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosisJulien Broséus, Sébastien Hergalant, Julia Vogt, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
Pageof 47

Showing results (431-440 of 466) with videos related to

Sort By:
Pageof 47
Blood|April 6, 2023
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemiaQu Jiang, Johanna Stachelscheid, Johannes Bloehdorn, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Leukemia & Lymphoma|March 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemiaFlorian Simon, Rudy Ligtvoet, Moritz Fürstenau, et al.
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|September 6, 2013
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndromeEkaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Lancet (London, England)|May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Nature Communications|January 19, 2023
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosisJulien Broséus, Sébastien Hergalant, Julia Vogt, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
Pageof 47